# A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple Myeloma

> **NCT05271682** · PHASE1 · UNKNOWN · sponsor: **Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** FHND6091

## Key facts

- **NCT ID:** NCT05271682
- **Lead sponsor:** Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-22
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2023-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05271682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05271682, "A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05271682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*